Date post: | 27-Jan-2017 |
Category: |
Health & Medicine |
Upload: | uc-san-diego-antiviral-research-center |
View: | 454 times |
Download: | 0 times |
The UC San Diego AntiViral Research Center sponsors weekly presentations by infectious disease clinicians, physicians and researchers. The goal of these presentations is to provide the most current research, clinical practices and trends in HIV, HBV, HCV, TB and other infectious diseases of global significance. The slides from the AIDS Clinical Rounds presentation that you are about to view are intended for the educational purposes of our audience. They may not be used for other purposes without the presenter’s express permission.
AIDS CLINICAL ROUNDS
A"Decade"of"Trea,ng"HCV"in"Pa,ents"with"Ongoing"Barriers"to"Care
Edward&Cachay&MD,&MAS&
Associate&Professor&of&Clinical&Medicine&
October&16,&2015&&
HCV"is"a"disease"of"the"disenfranchised"
2&
14&17& 19&
29&35&
50&
90&
0&
10&
20&
30&
40&
50&
60&
70&
80&
90&
100&
1&
%"HCV
"an(
body"posi(ve"
US&populaHon&
&AA&born&in&1950s&
Hospitalized&paHents&
Severely&mentally&ill&
Prisoners&Homeless&people&
People&IDU&≤&10&yrs&
People&IDU&>&10&yrs&
February"2008
• Rates&of&hepaHHs&C&were&increasing&in&the&general&populaHon&and&~&10&Hmes&higher&among&HIV&infected&paHents.&
• HIV&coUinfected&paHents&with&hospital&inpaHent&care&consHtuted&7.5&Hmes&as&many&hospitalizaHons&and&incurred&2.9&Hmes&the&charges&in&1995,&relaHve&to&all&HIV&hospitalizaHons&and&charges.&&
• In&contrast&to&the&general&populaHon,&rates&in&HIV&infecHon&represented&incident&cases.&
&
Hepatology:"2005,"42:"1406J13"
HCV&incidence&in&HIV&MSM&in&relaHonship&to&calendar&year&
Rate/&100UPY&
MetaUregression&Polynomial&fit&&&&&&&&&&(with&95%&CI)&
Year&of&esHmate&
Tim"who"was"32yo"was"admiMed"to"our"ICU"in"April"2007
• Tim"suffered"a"massive"myocardial"infarc,on"resul,ng"in"severe"conges,ve"heart"failure.
• "Suspected"induced"by"intravenous"methamphetamine"use. • Tim"was"diagnosed"with"HIV"and"also"HCV. • Tim"had"history"of"bipolar""disorder,"he"acknowledged"a""prior"suicidal"aMempt"at"age"21"while"‘under"the"influence’.
• CD4:"450,""HIV"VL"load">750,000"copies/ml"(at"diagnosis) &&
March"2008":"Referred"for"HCV"treatment"considera,on:
• HCV"genotype"3""and"HCV"viral"load"HCV"RNA"9’000,000 • He"had"started"HAART"2"months"prior • Grade"I"liver"enzyme"eleva,on,"albumin"4.6,"INR:"1.0"and"had"‘a#normal#looking#liver#on#a#CT#scan’"while"in"the"ICU.
• Tim"said"“my"liver"is"fine"and"does"not"bother"me"all”."
• Nick"has"Ryan"White"insurance
• Tim"was"at"the",me"on"a"rehabilita,on"program"in"San"Marcos."
&
Thinking&of&HCV&treatment&opHons&in&2007,&was&Tim&a&good&candidate&for&HCV&therapy?&&
1. Yes&2. No&&
The"conven,onal"approach:
• HCV>&3&considered&to&have&more&favorable&responses&to&PegUIFN&and&ribavarin&(&~50%).&
• CoUmorbidiHes&could&be&exacerbated&during&HCV&therapy.&
• Psychiatry&issues&would&likely&become&too&challenging.&
“&No&major&evidence&of&liver&fibrosis,&conHnue&rehabilitaHon,&treat&your&HIV,&follow&closely&with&your&PMD,&remain&absHnent&and&RTC&in&1&year…”&
Survival&by&HCV&AnHbody&Status&at&Clinic&Entry,&adjusted&for&Entry&CD4.&Owen&Clinic,&n&=,&5,978&
What"propor,on"of"HIV"pa,ents"with"known"HCV"and"in"HIV"care"were""treated"for"HCV"in"the"United"States"at"the"end"of"2010?
1.&Less&than&3%&
2.&5%&
3.&8%&
4.&15%&
5.&30%&
In"average"in"less"than"2.5%"of"pa,ents"coJinfected"with"HIV/HCV"were"cured"of"HCV""at"the"end"of"2012
100%&paHent&with&known&HIV/HCV&
&
never&treated&
25%&adverse&events&
10%&lost&to&followUup&
35%&sustained&viral&response&
30%&virological&failure&
Factors"that"contribute"to"low"HCV"treatment"uptake"among"HIV"coJinfected"pa,ent"s
Pa(ent"" &Provider"
Medical"system"
Limited&tesHng¢ers&
Low&№&providers&confident&delivering&HCV&
treatment&
Too&complex&percepHon:&A. PaHents&B. Management&
Depend&on&subUspecialty&clinic&
Too&much&paper&work:&A. PaHent&access&&B. Underinsured&
Low&reimbursement&incenHve&
Adapted from Grebely et al. 2013. JID; 207 (Suppl 1)
The"problem"is"not"limited"to"the"USA
From 1947 HIV-infected patients included, with a median follow-up time of 107 months (IQR: 57–156), only 23% received treatment for HCV (456 patients)
Grint D et al. HIV Med. 2013;14:614-23
0.00"
1.00"2.00"
3.00"
4.00"
5.00"6.00"7.00"8.00"
9.00"
Incide
nce&pe
r&100&PYFU
&
1998" 2000" 2002" 2004" 2006" 2008" 2010"
Incidence&rate&of&uptake&of&HCV&treatment&in&EuroSIDA&by®ion&
South&
North&
West&
East&C&
East&&
Copyright © Edward Cachay MD, MAS.
April"2008:"Shortage"in"staff"and"reimbursement"became"major"disincen,ves"for"on"site"subJspecialty"care"for"our"HCV/HIV"pa,ents."
HIV&provider&
Pharmacist&
Psychiatrist&
Substance&counselor&
UCSDGOwen"Hepa((s"Clinic"
is"born..."
Copyright © Edward Cachay MD, MAS.
Our&Goal:&To&improve&the&efficiency&of&the&HCV&staging&process&of&paHents&coUinfected&with&HIV/HCV&and&to&increase&the&absolute&number&of&paHents&&who&start&and&complete&treatment&&for&HCV&at&any&given&Hme&point.&
Owen"coJinfec,on"hepa,,s"clinic
HIV/HCV"coJinfected"pa,ents"had"more"coJmorbid"condi,ons"
The&median&№&of&comorbid&condiHons&was&greater&for&persons&with&HCV&coUinfecHon&(p<0.0001)&
0%"
10%"
20%"
30%"
40%"
50%"
0" 1" 2" 3+"№"of"comorbid"condi(ons"
Percen
tage"with
"con
di(o
ns"
HIV&monoinfected&
HIV/HCV&
Goulet'et'al.'AIDS'2005;'19'(suppl'3):'S99:S105'Copyright © Edward Cachay MD, MAS.
n=&25,116&&
Among"HIV/HCV"coJinfected"pa,ents"there"is"a"high"prevalent"of"low"health"literacy,"ongoing"substance"dependences,"neuropsychiatry""disorder"and"unstable"housing
Illegal&substance&use&
Neuropsychiatry&disease&Alcohol&dependence&
Poverty&
Cachay et al. AIDS Res Ther 2011, 8:e29
HIV
control
BA
RR
IER
S
LIV
ER
status
Co-m
orbidities The Owen Hepatitis Co-Infection staging table of HCV among HIV-infected patients
Lesson"#1:"More"than"assessing"liver"fibrosis…
Copyright © Edward Cachay MD, MAS.
The"‘CCR’"rule"and"prospec,ve"engagement"in"care:
• Commitment:&HIV&viral&load&undetectable&
• Consistency:&Follow&through&with&medical&&&&&
&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&recommendaHons&and&or&appointment&
• Reliability:&Avoid&‘no&shows’&,call&to&‘reschedule’.&
Copyright © Edward Cachay MD, MAS.
Key"prac,cal"points
• No&reUschedule&penalty&for&late&arrivals&• Always&it&is&a&good&Hme&to&start&over&again&
• ‘Cutback’&as&much&as&you&can&but&‘come&back’&no&maqer&what&
• SD&needle&exchange&program&/&methadone&clinics&
Clinic"visit"schedule"for"HIV"pa,ents"on"HCV"treatment"based"on"their"specific"barriers"and/or"medical"coJmorbidi,es"(in"weeks)
! 0! 1! 2! 3! 4! 5! 6! 7! 8! 9! 10! 11! 12! 14! 16! 18! 20! 22! 24! 26! 28! 30! 32! 34! 36! 40! 44! 48!
Group&1& ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !
Pharmacists!! X! !!!!!!!!!X! !!!!!!!!!!X! ! ! ! X! ! ! ! X! ! X! ! X! ! X! ! X! ! X! ! X! X! ! X!
Providers! X! ! ! ! X! ! ! ! X! ! ! ! X! ! X! ! X! ! X! ! X! ! X! ! X! X! X! X!
Group&2& ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !
Pharmacists! X! X! X! X! X! ! X! ! X! ! X! ! X! X! ! X! ! X! ! X! ! X! ! X! ! X! ! X!
Providers! X! ! ! ! X! ! ! ! X! ! ! ! X! ! X! ! X! ! X! ! X! ! X! ! X! ! X! X!
Group&3& ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !
Pharmacists! X! X! ! X! ! X! ! X! ! X! ! X! ! ! X! X! X! X! X! ! X! ! X! ! X! ! X! X!
Providers! X! X! X! X! X! ! X! ! X! ! X! ! X! X! X! X! X! X! X! X! X! X! X! X! X! X! X! X!
!
Homeless1!
Group 1: patients without major significant medical comorbidity, social barriers and no ongoing illicit substance use Group 2: patients with ongoing substance use (including intravenous) and/or homelessness Group 3: patients with severe neuropsychiatry disease (including prior suicidal attempts) and/or medical comorbidity
Cachay et al, AIDS Res Ther. 2013 Mar 28;10(1):9
Lesson:&One&size&does¬&fit&all&
Copyright © Edward Cachay MD, MAS.
What"happened"with"Tim?
05/2008&
No"show"
"Completed"Echocardiogram"
HCV&Treatment&iniHaHon&
1&2&
4&
5& SVR&
3.&HIV&VL&UD&
End&HCV&therapy&
Psych"
“ProspecHve&engagement&in&care”&
Copyright © Edward Cachay MD, MAS.
06/2008& 06/2008& 07/2008&07/2008&
Call"to"reGschedule"
07/2008& 08/2008& 08/2009&09/2008&
02/2010&
‘Valida,on"of"the"HCV/HIV"primary"care"model"’
SubGspecialty"model (January"2005GMarch"2008)
N&=152
N&=&22
N&=&199
Ini(al" evalua(on
study inclusion
Received"HCV"treatment
N&=146
N&=39
Primary"care"Model (April"2008"–"June"2010)
N&=&195
Excluded"pa(ents"(n"="47) UEntered&on&HCV&treatment:&9 UUndetectable&HCV&viral&load:&13& UPursued&clinical&trial:&11 UIncomplete&staging:&10 UTreatment&beyond&3/08:&4
Excluded"pa(ents"(n"="49) UEntered&on&HCV&treatment:&7 UUndetectable&HCV&viral&load:&6 UPursued&clinical&trial:&2 UIncomplete&staging:&12 UTreatment&beyond&8/11:&22
Untreated"pa(ents"(n=130) UAdvanced&cirrhosis:&13&UU&Uncontrolled&AIDS:&9& UPaHent&choice:&19 UPrior&nonUresponse:&6 ULost&to&followUup:&45&U&Drug/alcohol:&8 UUnstable&psych:&12 U&Homelessness&/language&literacy:&18
Untreated"pa(ents"(n=107) UAdvanced&cirrhosis:&17&UUncontrolled&AIDS:&22& U&&PaHent&Choice:&29 U&&&Prior&nonUresponse:10 U&&&Lost&to&follow&up:&22 U&&&Unstable&psych:&5 U&&&&Drug/alcohol&use&&&U Homelessness&/language&literacy:& 1
U The&referral&rate&did¬&differ&during&the&two&periods&(0.10&vs.&0.12/paHentUyr,&p = 0.18).&
&U Similar&treatment&disconHnuaHon&rates&due&to&
adverse&events&(29%&vs.&16%),&loss&to&followUup&(8&vs.&8%),&Owen&vs&subUspecialty,&respecHvely.&
&U Increase&trend&to&higher&HCV&SVR&(44&vs.&35%)&
for&Owen&vs.&&SubUspecialty&model,&respecHvely.&
Cachay&et&al.&AIDS&Res&Ther.&2013&
Clinic"Model HighGrisk"(n="17)
NonGhighGrisk""(n=31)
P"value
№&PaHents&with&Sustained&viral&response&(%) 5(29) 16(52) 0.14
№&PaHents&who&disconHnued&HCV&therapy&due&to&nonUviral&response&(%)
2(12) 7(23) 0.36
№&PaHents&who&disconHnued&HCV&therapy&due&to&treatmentUrelated&side&effects&(%)
6(35) 8(26) 0.49
№&PaHents&lost&to&followUup&(%) 3(18) 1(3) 0.08
Cachay et al, AIDS Res Ther. 2013 Mar 28;10(1):9
Early"preliminary"observa(ons:""Successful"HCV"treatment"of"HIV"pa(ents"with"ongoing"barrier"to"care"is"possible"
There&were&no&differences&between&groups&in&age,ðnicity,&liver&fibrosis,&proporHon&of&HCV&genotype,&baseline&laboratory&exams&,&HCV&RNA&,&CD&and&HIV&VL.&&
Cure"of"HCV"means"a"lot"to"our"pa,ents
Cachay"et"al."2011,"AIDS"Res"Ther.;8:29"
0" 5" 10" 15" 20" 25"1" 4"3"2" 5" 6"
40"
60"
80"
100"
120"
40"
60"
80"
100"
120"
2011:"HRSA""‘UCSD"CoJinfec,on"Clinic"a"model"to"replicate’
PegUIFN&+&&RBV&
PegUIFN&+&RBV&+&DAA&
DAA&combinaHon&
2016&2011& 2013&2012& 2014& 2015&2010&
Treatment"complexity"
HIV"primary"care/ID"clinics"to"treat"HCV""
2005&
Lesson"#3:"Do"not"do"harm
• Use&of&triple&therapy&with&pegylatedUInterferon&+&Ribavirin&+&Telaprevir&promised&~&75%&chance&of&HCV&cure&
• Following&treatment&of&our&first&25&paHents&with&triple&therapy,&we&observed&something&different:&&
&&‘&One&of&two&paHents&treated&with&HCV&triple&therapy&could&be&cure&of&HCV&…but&at&&the&cost&of&one&in&two&developing&serious&adverse&reacHons&(Grade&III&or&IV)&that&required&hospitalizaHon’.&
Cachay&et&al.&AIDS.&2013;27(18):2893U7.&
HCV"treatment"uptake"at"UCSD"Owen"Clinic"
Cachay et et al. Plos One 2014
2008& 2009& 2010& 2011& 2012&0&
1&
3&
2&
4&
5&
6&
7&
8&
HCV
&treatm
ent&u
ptake&pe
r&100P
YFU&
Copyright © Edward Cachay MD, MAS.
2013&
Mean&
95%&&CI&
2014&
May"2013:
&
• We&advocated&for&IFNUfree&DAA&combinaHons&for&our&paHents,&before&any&professional&guideline&was&available.&
Sofosbuvir:"HCV"vs"HCV/HIV,"in"genotype"1,2"and"3
SOF/P/R&& SOF/R& GT2&naive&
89& 89&
68&
95& 94&90&
93& 91&
0&
10&
20&
30&
40&
50&
60&
70&
80&
90&
100&SV
R"rate"HCV& HIV/HCV&
AnHviral&Drugs&Advisory&Commiqee&MeeHng,&FDA&review,&10/24/13&&C208,&C216,&C206,&C212,&HPC3007,&Dieterich,&14th&European&AIDS&Conference,&2013;&&
Lawitz&et&al.&NEJM&2013&
81&89&
79&88&
GT2&experienced&
GT3&naive& GT3&experienced&
Lesion:&‘HIV&is&no&longer&a&poor&prognosHc&factor&for&response&to&HCV&treatment’&
We"were"looking"forward"to"the"exci,ng",mes"coming"ahead!
IFN& pegIFNURBV& Triple& All&oral&DAA&
Sustaine
d&viral&respo
nse&(cure)&&
1990s& 2000s& 2011& 2014&
10%&
35%&
65%&
>&90%&
No.&
Adapted from Expert Opin Pharmacother. 2013;14:1161-70
Copyright © Edward Cachay MD, MAS.
Treatment"only"helps"those"who"receive"it
100&%& 100&%&& 100&%&
20&%& 20&%&
10&%& 19&%&
90&%&
85&%&
All&HCV&PaHents&
Diagnosis&and&therapy&
Cure&
PegUIFN/RBV& 95%&SVR&95%&SVR,&increase&diagnosis&and&
linkage&to&treatment&
1"pill"of"Sofosbuvir"~"1,000$
Consequences"of"high"price"of"HCV"medica,ons
0&
1&
2&
3&
4&
5&
6&
7&
8&
1& 2& 3& 4&2013&Q4&
Q2& Q3& Q4& 2015&Q1&
2014&
$&Billions&per&month& Sales&>&$&2.5&
billion/month&
Profits&&>&$&1.4&billion/month&
Source:&Gilead&sales,&adapted&from&IDWeeK&2015.&Sunday&11&
• U.S.&is&the&only&country&that&places&no&limit&to&drug&prices&
• Government&grants&drug&patents&under&HatchUWaxman&Act&
• Purpose:&to&incenHvize&development&of&the&drugs&the&public&needs&
• When&these&drugs&are&placed&out&of&reach&of&the&public,&government&needs&to&weight&preventable&morbidity&and&mortality&vs.&company&monopoly&pricing&rights.&
• Federal&law&28&U.S.C.&§&1498&(a)&allows&government&to&use&patent&invenHon&without&permission&of&the&owner.&
The"HCV"market"running"and"their"impact"on"lowering"the"prices"
Gilead"
AbbVie"
BMS"
Janssen"
Merck"
&&&&&&&&&
Roche&Boehringer&
Consequences"of"high"price"in"2014
• Conflict&&between&provider,&paHent&and&payer&over&raHoning&&UU&&“you&must&wait&unHl&you&have&severe&liver&damage&to&g&t&treated”&
&UU&“&You&need&to&be&clean&and&sober&to&be&treated”&&
&UU&“&I&am¬&worth&the&treatment”&
2014:"Payer"restric,ons"(Public"and"private)..aka..
Alcohol&and&substance&use&&
Fibrosis:&Most&state&Medicaid&required&F3/4&&&&&&&&&&&&&&&&6&States&required&liver&biopsies&&
Prescriber&specialtyU&monopoly&&&
Onerous&preUauthorizaHon&procedures:&&&&&&&&&&&&&&&&&&~&12&hours&per&paHent&&
U Contradict&medical&specialty&guidance&
&U Purely&for&financial&reasons&&&U Discriminatory&&U Illegal&&
HCV is the only disease where there has to be significant organ damage to treat.
Ann Intern Med. 2013;158(9):658-666.
Persons with HIV had liver fibrosis measurements equal to those of persons without HIV, who were, on average, 9.2 years older
REVEALJHCV:"‘HCV"is"a"systemic"infec,on’"
Lee"et"al."J"Infect"Dis"2012;"206:"469J77.""
2.8
1.5
1.3
1.4
5.4
21.6
12.5
1.9
//
All causes death Liver-related
Liver cancer
Cirrhosis
Extrahepatic Cancers*
Cardiovascular
Kidney
Adjusted hazard ratios
HCV Ab-pos vs HCV Ab-neg
U 23,820"adults"followed"for"a"mean"of"16.2"years"U 1095"HCV"Ab+"(4%)"U 69%"of"HCV"Ab+"were"HCVGRNA"pos"U 2394"deaths"during"the"study"period"
*esophagus, prostate & thyroid
""Hepa,,s"C"surpasses"HIV"as"a"cause"of"death"in"the"US"
Rate"per""100"000"Persons"
2000"1999" 2001" 2002" 2003" 2004" 2005" 2006" 2007"
Hepa((s"B"
Hepa((s"C"
HIV"
adapted from Ann Intern Med. 2012, 156:271-8
0&1&
2&
3&
4&
5&
6&
7&
HIV" Chronic"liver"disease"
Alcohol"related"condi(ons" Hepa((s"B"
&1.8&(1.6&U2.0)& 32.1&(31.0U33.3)& 4.6&(4.4&U4.8)& 29.9&(26.5U33.6)&
Why&do&we&have&to&exclude&people&who&use&drugs&or&alcohol?&
The"most"frequent"reason"for"not"ini,a,ng"HCV"therapy"is"the"presence"of"ongoing"barriers"to"care"in"the"IFNJera
Known"HCV"infec,on"with"established"HIV"care 100%"(n=751)"
Referred"for"HCV"treatment" 40%"(n=301)"
AMended"≥"1"clinic"visit"for"HCV"evalua,on" 37%"(n=281)"
Final"decision"is"made"regarding" HCV"therapy"ini,a,on
33%"(n=248)"
Start"HCV"treatment "12%"(n=88)"
""""HCV"cure" """""5%(n=41)"
Cachay"et"al."PLoS"One."2014";9:e102883
&&&&&&&&U&Barriers&to&care:&78&of&195&(40%)&U&PaHent&did¬&want&IFNUbased®imens:&45&of&195&(23%)&U&Advanced&liver&disease:&34&of&195(18%)&&U&Prior&null&response&:&16&of&195(8%)&U&Spontaneous&clearance:&16&of&195(8%)&U&ContraindicaHon&to&IFN/or&RBV:&6&of&195(3%)&
Reasons&for¬&starHng&HCV&treatment:&
Where"do"we"stand"in"this"fight?" MedicaHon&manufacturer& InsurancesU&
Health&payees&
Nothing"speaks"beMer"than"data"and"that"is"the"best"way"to"advocate"for"our"pa,ents
HCV"treatment"regimens"used"in"HIV"coJinfected"pa,ents"in"2014"at"UCSD
Genotype" N"="30" Regimens"1a& &23& &&&RBV&+&SOFU24&weeks&&&&&&&&&&&&&&&&&&&&&&&&&&&&(&2)&
&&&SIM&+&SOFU12&weeks&&&&&&&&&&&&&&&&&&&&&&&&&&&&(12)&&&&SIM&+&SOFU24&weeks&&&&&&&&&&&&&&&&&&&&&&&&&&&&(&4)&&&&SIM&+&SOF&+&RBVU24&&weeks&&&&&&&&&&&&&&&&(&1)&&&&LDV&+&SOFU12&weeks&&&&&&&&&&&&&&&&&&&&&&&&&&&&(&2)&&&&LDV&+&SOFU24&&weeks&&&&&&&&&&&&&&&&&&&&&&&&&&&(&2)&
2& &3& &&&SOF+RBVU12&weeks&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&(&3)&
3& &2& &&&SOF+RBVU24&weeks&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&(&2)&
4& &2& &&&SIMF+SOF&+&RBVU12&weeks&&&&&&&&&&&&&&&&&(&1)&&&&SIM&+&SOFU24&weeks&&&&&&&&&&&&&&&&&&&&&&&&&&&&&(&1)&
Cachay et et al. OFID under review
Characteris,cs"of"pa,ents"with"cirrhosis"("n=22)
Genotype&"""X""&
&&&&&&&&&&1a&&&&&&&&&&&2&&&&&&&&&&&4&
&&&&19&(86%)&&&&&&1&(5%)&&&&&&&2&(9%)&
Median&&MELD&score&&(range)& &&&11&(6U20)&Prior"liver"decompensa(on""&&Ascites&&&&HepaHc&encephalopathy&&&&Esophageal&varices&bleeding&&
10"&9&&7&&&3&
Cachay et et al. OFID under review
"90%"of"our"treated"pa,ents"will"not"fulffil"clinical"trial"enrollment""
5&
2& 2& 2&
4&
2&
Comorbilidad& Barreras&de&salud&
TARGA&compleja&+&comorbilidad&
comorbilidad&+&barreras&de&
salud&
TARGA&compleja&+&barreras&+&
comorbilidad&
Child&CUcirrosis&
Cirrho(cs"pa(ents"with"GT"1a"(n=17)"
Comorbidity&& Barriers&to&care&
Complex&ART&&+&
&comorbidity&
Comorbidity&+&&
Barriers&to&care&
Complex&ART&&+&
Barriers&+&
&comorbidity&
Child&C&Cirrhosis&&
Cachay et et al. OFID under review
0
75 83.34
SMV + SOF± RBV x 12 Wks
Real"world
. 1Dieterich D, et al. AASLD 2014. Abstract 46.
n =
UCSD
SV
R 4
(%)
100
80
60
40
20
COSMOS F3/F4
N=&145& N=&30&N=&13&
93 89.6
N=&29&
TRIO&
Mt"Sinai
81.08
N=&37&
"Penns."/"New"Jersey
N=33&
83.03
Northwest
HIV&cohorts&
90
80
Cachay et et al. OFID under review
What"is"the"impact"of"barriers"to"care"on"HCV"treatment"response?"
• Ongoing&barriers&to&care&&definiHon:&drug/alcohol&use,&homelessness&,&poverty&and&neuropsychiatry&disease.&
• RetrospecHve&comparison&of&all&paHents&treated&an&Owen&HCV&clinic&
• Our&treatment&protocol&for&treaHng&HCV&among&paHents&with&barriers&to&care&has&been&unchanged&since&clinic&incepHon&(2008),&we&compared&treatment&outcomes&across&HCV&treatment&era&:&
&&&&U&Dual&therapy&(pegylated&interferon&plus&ribavirin,&2008U2011);&&
&&&&U&Triple&therapy&(pegUIFN&plus&ribavirin&and&telaprevir,&2011U2013);&&
&&&&U&IFNUfree&DAA&therapy&(2014&)&
Cachay et et al. IDweek 2015- abstract 1672
Cachay et et al. IDweek 2015- abstract 1672
Results:"
• HCV&eradicaHon&among&paHents&with&ongoing&barriers&to&care&improved&from&40%&(95%&CI:&21U61)&to&75%&(95%&CI:&48U93)&in&the&dual&and&DAA&eras,&respecHvely.&
• Using&DAA&and&an&inclusive&HCV&treatment&protocol&75%&of&HIV/HCV&treated&paHents&with&ongoing&barriers&to&care&achieved&HCV&eradicaHon.&
S,ll"much"remains"to"be"done
Conclusions:
• A&HIV&primary&care&model&is&a&effecHve&way&to&increase&HCV&treatment&uptake&among&HIVUinfected&paHents.&
• Our&data&supports&that&HIVUinfected&paHents&with&ongoing&barriers&to&care&(e.g.&drug/alcohol&use)&achieve&similar&proporHons&of&HCV&cure&than&paHents&without&barriers&to&care&&if&they&seek&voluntarily&HCV&treatment.&
• We&need&collaboraHons&of&all&fronts&in&our&society&to&effecHvely&treat&HCV&in&our&paHents:&Pharma,&Public&payers,&Local&&&federal&government.&&
Acknowledgements
U Christopher&Mathews&
U Chuck&Hicks&U Robert&Schooley&U Alex&Kuo&&U My&Owen&colleagues&
U Jerry&Collins&U Susan&McQuillen&
&&
• Owen&HCV&team&U&Craig&Ballard&
U&David&Wyles&
U Bradford&Colwell&U Francesca&Torriani&U Miguel&Goicoechea&(2008U2011)&
U Lucas&Hill&
People&with&ongoing&barriers&to&care&are&a&reflecHon&of&us&as&society.&They&provide&us&the&opportunity&to&look&at&the&place&where&we&live&from&a&different&perspecHve.&Working&together&with&tolerance&and&inclusion&are&key&to&promote&the&common&good&of&everyone&in&our&society.&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&Edward&Cachay&